Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.44 USD | +0.30% | -2.10% | -10.63% |
10/05 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
01/05 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.63% | 622.49Cr | |
+4.97% | 11TCr | |
+11.10% | 11TCr | |
-0.38% | 2.23TCr | |
-12.37% | 2.21TCr | |
-7.66% | 1.87TCr | |
-36.52% | 1.76TCr | |
-9.55% | 1.69TCr | |
+4.48% | 1.38TCr | |
+34.81% | 1.25TCr |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Transcript : Exelixis, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04